Investors / United Kingdom / Cancer Research Horizons
Cancer Research Horizons
Investor · London, United Kingdom · Europe
Cancer Research Horizons is a wholly owned subsidiary of Cancer Research UK and serves as its translational arm, helping advance, develop and commercialise research innovations. It combines in-house drug discovery and development expertise with Cancer Research UK's researcher and clinician network, partners and investment to move science toward treatments and diagnostics.
Invests inHealthcare & Biotech
In its own wordsoncologydrug discoverydiagnosticstherapeuticslife sciencesseed funding
Your fit with Cancer Research Horizons
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCancer Research Horizons lists 6 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 60% of its companies are based in United Kingdom. It invests most often alongside 4BIO Capital, AIN Ventures and Brandon Capital.
Counts come from funding rounds that name Cancer Research Horizons, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 67% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 98th | 33% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 59th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| 4BIO Capital | 1 |
| AIN Ventures | 1 |
| Brandon Capital | 1 |
| Calculus Capital | 1 |
| Casdin Capital | 1 |
| Correlation Ventures | 1 |
| Future Planet Capital | 1 |
| IQ Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Cancer Research Horizons head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Cancer Research Horizons| Date | Company | Stage |
|---|---|---|
| 5 Nov 2026 | Series A | |
| 29 Sept 2026 | Seed | |
| 6 Oct 2025 | Series A |
Round details for Cancer Research Horizons
Amounts, full round histories and every co-investor in Cancer Research Horizons' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company builds innovative diagnostic and digital solutions to transform emergency care | Healthcare & Biotech | Sept 2026Seed | Page + round | |
| Alethio Therapeutics is developing therapies to improve outcomes for patients with myeloproliferative neoplasms, a group of blood cancers. | Healthcare & Biotech | Nov 2026Series A | Page + round | |
| Myricx Bio is a biotech company discovering and developing a novel class of payloads for antibody drug conjugates to treat cancer. | Healthcare & Biotech | Portfolio page | ||
| Nexomic uses frontier AI to decode the hidden biology driving treatment response, resistance, and disease evolution. | Healthcare & Biotech | Portfolio page | ||
| Oric Pharmaceuticals develops and commercializes innovative therapies to address cancer resistance | Healthcare & Biotech | Portfolio page | ||
| Trogenix develops precision cancer treatments using gene therapy | Healthcare & Biotech | Oct 2025Series A | Funding round |
About this data
site last read 5 Nov 2026- Site
- cancerresearchhorizons.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 6 Oct 2025
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Cancer Research Horizons' profile as data
Pull Cancer Research Horizons' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/cancerresearchhorizons.com
# also
GET /v1/firms/cancerresearchhorizons.com/portfolio
GET /v1/firms/cancerresearchhorizons.com/coinvestors
GET /v1/firms/cancerresearchhorizons.com/news